First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation.

Journal:

Journal of Clinical Oncology

Published:

2025-11-07

DOI:

10.1200/jco-25-00559

Affiliations:

19

Authors:

22

Go to article

Institutions	Authors	Share
Bicycle Therapeutics Limited, United Kingdom (UK)	7.000000	0.32
Sarah Cannon Research Institute (SCRI), United States of America (USA)	2.000000	0.09
Institute Gustave-Roussy (IGR), France	2.000000	0.09
Bergonié Cancer Institute, France	1.500000	0.07
The University of Texas MD Anderson Cancer Center, United States of America (USA)	1.000000	0.05
Centre Léon Bérard (CLB), France	1.000000	0.05
START-Madrid-FJD, Spain	1.000000	0.05
Vall d'Hebron University Hospital (HUVH), ICS, Spain	1.000000	0.05
August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Spain	1.000000	0.05
Sarah Cannon Research Institute - UK, United Kingdom (UK)	1.000000	0.05
University of Bordeaux, France	0.500000	0.02
Case Western Reserve University (CWRU), United States of America (USA)	0.500000	0.02
The University of Manchester (UoM), United Kingdom (UK)	0.500000	0.02
The Christie NHS Foundation Trust, United Kingdom (UK)	0.500000	0.02
UH Seidman Cancer Center, CWRU, United States of America (USA)	0.500000	0.02
Vita-Salute San Raffaele University (UniSR), Italy	0.500000	0.02
IRCCS San Raffaele Hospital (HSR), Italy	0.500000	0.02

Interested in Oncology and Carcinogenesis?